Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Conditions
Interventions
Intervention1: Mycofenolate Mofetil: up to 2 grams per day for 1 year
Control Intervention1: Standard of care: Standard of care as deemed fit by t he treating physician
Sponsors
Institute of Postgraduate Medical Education and Research
Eligibility
Inclusion criteria
Inclusion criteria: RT-PCR confirmed case of COVID 19 infection. Patients with confirmed case of COVID 19 with persistence of lung lesion on HRCT after 6weeks of infection Normal hepatic and renal function Participants can understand the study and sign informed consent for the study.
Exclusion criteria
Exclusion criteria: Previous or concurrent malignancies Any previous immunosuppressive therapy/ radiotherapy/ or HIV Medical or psychiatric conditions that compromise the patients ability to give informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in 6 minutesâ?? walk test at 3, 6 and 12 months after therapy. Change in FVC at 3,6 and 12 months after therapy. Radiological resolution at 6th and 12 months of therapy Timepoint: Baseline, 3, 6 and 12 months | — |
Secondary
| Measure | Time frame |
|---|---|
| HAQ Prevalence of infections in different groups Timepoint: 3, 6, and 12 months | — |
Countries
India
Contacts
Public ContactAmitabha Sengupta
Institute of Postgraduate Medical Education and Research
Outcome results
None listed